Company intelligence / Profile preview

MAXO Reading Center

Ownership: Private
Development stage: Other

Overview

MAXO is an ophthalmic reading center working closely with TFS HealthScience, providing evaluation and data analysis services for clinical trials, notably supporting studies in dry eye disease. They partner with RetinAI to integrate AI/ML-powered imaging analytics into ongoing ophthalmology studies.

Therapeutic areas: Ophthalmology
Modalities: Not explicitly stated; as a reading center in ophthalmology trials, likely supports imaging endpoints for multiple therapeutic modalities, but direct involvement in therapeutics not confirmed
Industry: Contract Research Organization

Partnerships

TFS HealthScience (global CRO)RetinAI (AI/analytics platform provider)

Beyond the preview

Go deeper on MAXO Reading Center.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAXO Reading Center.

Explore the full profile